Rochester

Talis Biomedical Announces Appointment of Brian Blaser as President, Chief Executive Officer and Director

Retrieved on: 
Monday, November 15, 2021
Health equity, University, Master of Business Administration, Maintenance, Abbott Laboratories, Industry, Private Securities Litigation Reform Act, Diagnosis, Laboratory, Engineering, Rochester Institute of Technology, Security (finance), Infection, Food, General Motors, Growth, COVID-19, Rochester, Emergency Use Authorization, Forward-looking statement, Annual report, Interim, Risk, Board, Abbott, Company, Regulation of tobacco by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, GLOBE, Johnson & Johnson, Business administration, EUA, EVP, Ortho Clinical Diagnostics, Patient, FDA, Kodak, Mechanical, Management, Pharmaceutical industry

MENLO PARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced the appointment of Brian Blaser to President, Chief Executive Officer and Director. Kim Popovits, currently serving as Interim Chief Executive Officer, will resume her role as Director on the Board of Talis. These changes will be effective December 1, 2021.

Key Points: 
  • MENLO PARK, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced the appointment of Brian Blaser to President, Chief Executive Officer and Director.
  • Kim Popovits, currently serving as Interim Chief Executive Officer, will resume her role as Director on the Board of Talis.
  • Mr. Blaser has more than 25 years of senior leadership experience in the in-vitro diagnostics industry, including 17 years at Abbott Laboratories.
  • He currently serves as an Executive Advisor to Water Street Healthcare Partners and as a Non-Executive Director on the board of Rockley Photonics.

Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Retrieved on: 
Wednesday, November 10, 2021
Neurodegeneration, SITC, Cancer, Security (finance), Ion, SEMA4D, COVID-19, Research, GPCR, Forward-looking statement, Inflammation, Neoplasm, U.S. Securities and Exchange Commission, SEC, Poster, Brain

ET on Saturday, November 13, and on the SITC 2021 virtual meeting platform from 7 a.m.

Key Points: 
  • ET on Saturday, November 13, and on the SITC 2021 virtual meeting platform from 7 a.m.
  • ET on Friday, November 12, 2021, until the virtual meeting platform is closed on January 9, 2022.
  • The Poster will also be available on Vaccinexs website starting on November 12, 2021, at: https://ir.vaccinex.com/presentations
    For more information about the SITC Annual Meeting please refer to the conference website.
  • Vaccinex, Inc.is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D).

OptimizeRx Reports Third Quarter 2021 Financial Results, Revenue Increased 53% in Continued Scale Up for Accelerated Growth

Retrieved on: 
Tuesday, November 9, 2021
Health, Contract, Corporate finance, RWE, Technology, Income, Growth, SVP, Partnership, Company, GLOBE, Solution, GAAP, ROI, Physician, Patient, Demandbase, Animal, Cryptocurrency, Bank, Management, Pharmaceutical industry, Risk management

Gross profit in the third quarter of 2021 increased 51% to $9.1 million as compared to the same year-ago period.

Key Points: 
  • Gross profit in the third quarter of 2021 increased 51% to $9.1 million as compared to the same year-ago period.
  • Gross profit margin in the third quarter of 2021 decreased slightly to 56.3% from 57.2% as compared to the same year-ago period.
  • Cash and cash equivalents totaled $85.0 million as of September 30, 2021 as compared to $83.9 million as of June 30, 2021.
  • Will Febbo, OptimizeRx CEO commented, We are pleased with the financial and operational progress of the quarter and remain on track to end 2021 strong.

Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Retrieved on: 
Tuesday, November 9, 2021
Neurodegeneration, Cancer, Security (finance), Ion, SEMA4D, COVID-19, Research, GPCR, Forward-looking statement, Inflammation, Neoplasm, U.S. Securities and Exchange Commission, SEC, Brain, Online shopping

The slide presentation will be available on Vaccinexs website 48 hours after the event at: https://ir.vaccinex.com/presentations

Key Points: 
  • The slide presentation will be available on Vaccinexs website 48 hours after the event at: https://ir.vaccinex.com/presentations
    For more information about the CTAD, please refer to the conference website.
  • The in-person program in Boston will be streamed live on the digital platform and become available on demand after 48 hours to registered participants.
  • Vaccinex, Inc.is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D).
  • Except as required by law, we assume no obligation to update these forward-looking statements.

Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 8, 2021
Cloud, Neurodegeneration, Population, Cognition, HD, Cancer, Dementia, Home After Three Months Away, State Administrative Expenses, AD, Security (finance), Composite, Technology, Ion, Apathy, COVID-19, Cash, Research, Tumor microenvironment, GPCR, Forward-looking statement, PHASE 2, Association, Emory University, Winship Cancer Institute, Inflammation, Neoplasm, Biotechnology, U.S. Securities and Exchange Commission, GLOBE, Brain, SIGNAL, Security, SEC, FDG-PET, Nasdaq, Patient, Head, Melanoma, G protein-coupled receptor, SEMA4D, Pharmaceutical industry, Medical imaging, Vaccine, Fine chemical, Cryptocurrency, Lithium

ROCHESTER, N.Y., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • ROCHESTER, N.Y., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.
  • We made steady progress on our pepinemab clinical programs since our last quarterly update.
  • Financial Results for the Three Months Ended September 30, 2021:
    Research and Development Expenses.
  • Vaccinex, Inc.is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D).

Predictive Analytics Solutions Create New Opportunities for Life Sciences to Address Delayed Diagnosis and other Challenges in Multiple Sclerosis Treatment

Retrieved on: 
Friday, November 5, 2021
Securities Exchange Act of 1934, HCP, Adoption, Journal of Clinical Psychology, Spinal cord, National Multiple Sclerosis Society, DMT, Education, Excoriation disorder, Organization, POC, Multiple sclerosis, Disease, Neurology, Technology, Insurance, Machine learning, Dizziness, Face, Research, Securities Act of 1933, Forward-looking statement, HIV disease progression rates, Fatigue, AI, Regulation, Perception, Pain, GLOBE, Awareness, HCPS, Solution, Journal, Diagnosis, Social Security Act 1938, DMTS, National Multiple Sclerosis Society, National Capital Chapter, Patient, MS, Brain, Medical device, Healthcare, Medicine

This can help get patients started on therapy earlier, with tailored adherence programs to address unique MS challenges to support patients to remain persistent on doctor-recommended therapies.

Key Points: 
  • This can help get patients started on therapy earlier, with tailored adherence programs to address unique MS challenges to support patients to remain persistent on doctor-recommended therapies.
  • However, early therapy initiation is often delayed by challenges in correctly diagnosing patients in a timely manner.
  • The application of AI-driven predictive analytics to real-world evidence can support earlier diagnosis by connecting otherwise disparate critical patient data points in real-time.
  • Even after patients are correctly diagnosed, they may delay treatment or opt for treatments that address sporadic MS attacks.

DSS Expands American Medical REIT with Acquisition of Three Established Acute Care Hospitals in Texas and Pennsylvania

Retrieved on: 
Thursday, November 4, 2021
Hospital, Quality, IPO, Length of stay, Association, Novena Global Lifecare, Health, Patient, Critical care, American Medical Response, NYSE, DSS, Leadership, American Association for Respiratory Care, Renewable energy, Company, Joint Commission, Medicare, CEO, Growth, Solution, American Association, REIT, Acquisition, AMRE, GLOBE, Real estate

The Hospitals are currently tenanted and operated by LifeCare Hospitals (together with its affiliates, LifeCare Hospitals), a specialty hospital operator with a focus on long-term acute and critical care.

Key Points: 
  • The Hospitals are currently tenanted and operated by LifeCare Hospitals (together with its affiliates, LifeCare Hospitals), a specialty hospital operator with a focus on long-term acute and critical care.
  • The Hospitals have a total capacity of 195 hospital beds spanning a gross floor area of approximately 320,000 square feet.
  • In 2015, the Hospitals were awarded the Quality Respiratory Care Recognition accolade issued by the American Association of Respiratory Care.
  • In connection with the acquisition of the Hospitals, DSS Securities, a wholly owned subsidiary of DSS, loaned AMRE $0.8 million and American Pacific Bancorp, Inc., a majority-owned subsidiary of DSS, loaned AMRE $13.9 million.

Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference

Retrieved on: 
Thursday, November 4, 2021
Research, GPCR, Cancer, Neurodegeneration, Neoplasm, Security (finance), U.S. Securities and Exchange Commission, SEMA4D, Ion, SEC, Conference, Brain, Jefferies, Forward-looking statement, Inflammation, Webcast, COVID-19, Nasdaq, GLOBE, GMT, Pharmaceutical industry

ROCHESTER, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, is scheduled to present virtually at the 12th Annual Jefferies London Healthcare Conference and invites investors to participate in virtual one-on-one meetings on Thursday and Friday, November 18th and 19th. Please see Presentation details below:

Key Points: 
  • For more information about the Jefferies London Healthcare Conference, please refer to the Jefferies conference website .
  • Vaccinexs presentation will also be available on the Jefferies website for 30 days after the conference.
  • Vaccinex, Inc.is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D).
  • Except as required by law, we assume no obligation to update these forward-looking statements.

Vaccinex to Present at the Virtual Huntington’s Study Group Meeting on November 4-6, 2021

Retrieved on: 
Monday, November 1, 2021
Research, SIGNAL, GPCR, Cancer, Neurodegeneration, Neoplasm, Brain damage, Security (finance), U.S. Securities and Exchange Commission, Patient, Manifest, SEMA4D, Ion, SEC, HD, Brain, Senior, Forward-looking statement, Inflammation, COVID-19, Nasdaq, GLOBE, Translational medicine, HSG, Pharmaceutical industry, Vaccine

D., Chief Operating Officer and Senior Vice President, Discovery and Translational Medicine, will present the poster SIGNAL Phase 2 Study Suggests that Pepinemab, Anti-SEMA4D Antibody, Provides Cognitive Benefit In Early Manifest Huntingtons Disease.

Key Points: 
  • D., Chief Operating Officer and Senior Vice President, Discovery and Translational Medicine, will present the poster SIGNAL Phase 2 Study Suggests that Pepinemab, Anti-SEMA4D Antibody, Provides Cognitive Benefit In Early Manifest Huntingtons Disease.
  • The poster that Dr. Evans will present will review the expanded post-hoc analysis of the SIGNAL study and provide preclinical mechanism of action data.
  • Note that Dr Zauderers slides and video presentation will be available on the Vaccinex website following conclusion of the meeting ( www.vaccinex.com ).
  • Vaccinex is focused on the development of pepinemab for the treatment of cancer and neurodegenerative diseases including Huntingtons and Alzheimers disease.

RCare and Special Care Systems Named to Top 100 by Rochester Chamber

Retrieved on: 
Monday, November 1, 2021
Quality of life, Last Time Around, Technology, Hospital, Industry, Health care, History, Laika (EHR testing framework), Greater, Communication, Leadership, Rights, Nursing care plan, Rochester, Growth, COVID-19, Solution, Steward Health Care System, Bank

WEBSTER, N.Y., Nov. 1, 2021 /PRNewswire-PRWeb/ --RCare, creator of advanced nurse call and monitoring solutions, and Special Care Systems, a healthcare communications integrator and RCare top distributor, have been named Top 100 Businesses for 2021 by the Greater Rochester Chamber.

Key Points: 
  • WEBSTER, N.Y., Nov. 1, 2021 /PRNewswire-PRWeb/ --RCare, creator of advanced nurse call and monitoring solutions, and Special Care Systems, a healthcare communications integrator and RCare top distributor, have been named Top 100 Businesses for 2021 by the Greater Rochester Chamber.
  • Special Care Systems integrates healthcare solutions from a variety of companies, including RCare, into customized systems for hospitals and senior care communities.
  • This is the third time Special Care Systems has received the Chamber Top 100 honor.
  • RCare was honored as a 2020 COVID-19 Health Care Hero by the Rochester Chamber, for its impact on the quality of health care during the pandemic.